Remi A Nout

Summary

Affiliation: Leiden University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Gynecol Oncol 126:466-73. 2012
  2. doi request reprint Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Cancer 48:1638-48. 2012
  3. pmc The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, P O Box 9600, 2300 RC, Leiden, The Netherlands
    Breast Cancer Res Treat 109:567-72. 2008
  4. doi request reprint Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 27:3547-56. 2009
  5. doi request reprint Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
    Lancet 375:816-23. 2010
  6. doi request reprint Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 29:1692-700. 2011
  7. doi request reprint Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Int J Radiat Oncol Biol Phys 81:e631-8. 2011
  8. doi request reprint Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 26:1525-35. 2013
  9. doi request reprint Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
    Inge C van Gool
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 29:174-81. 2016
  10. doi request reprint Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, The Netherlands
    Eur J Cancer 51:1742-50. 2015

Collaborators

Detail Information

Publications25

  1. doi request reprint Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Gynecol Oncol 126:466-73. 2012
    ....
  2. doi request reprint Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Cancer 48:1638-48. 2012
    ..The current analysis was done to evaluate long-term health related quality of life (HRQL), and compare HRQL of patients to an age-matched norm population...
  3. pmc The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, P O Box 9600, 2300 RC, Leiden, The Netherlands
    Breast Cancer Res Treat 109:567-72. 2008
    ..Knowledge of the contribution of non-disease related death or contralateral breast cancer to estimated recurrent disease rate and overall death rate is indispensable for a correct interpretation and comparison of outcome analyses...
  4. doi request reprint Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 27:3547-56. 2009
    ..Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective...
  5. doi request reprint Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
    Lancet 375:816-23. 2010
    ..This study established whether vaginal brachytherapy (VBT) is as effective as pelvic external beam radiotherapy (EBRT) in prevention of vaginal recurrence, with fewer adverse effects and improved quality of life...
  6. doi request reprint Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 29:1692-700. 2011
    ....
  7. doi request reprint Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Int J Radiat Oncol Biol Phys 81:e631-8. 2011
    ....
  8. doi request reprint Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 26:1525-35. 2013
    ..These observations suggest that ARID1A is a causative gene, instead of a target gene, of microsatellite instability by having a role in epigenetic silencing of the MLH1 gene in endometrial cancer. ..
  9. doi request reprint Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
    Inge C van Gool
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 29:174-81. 2016
    ..The high frequency of L1CAM expression in high-risk endometrial cancers suggests that it may also be a promising therapeutic target in this tumor subset. ..
  10. doi request reprint Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, The Netherlands
    Eur J Cancer 51:1742-50. 2015
    ..However, its role in relation to type of recurrence and adjuvant treatment is not well defined, and there is significant interobserver variation. This study aimed to quantify LVSI and correlate this to risk and type of recurrence...
  11. doi request reprint Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial
    Stephanie M de Boer
    Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands Electronic address
    Int J Radiat Oncol Biol Phys 93:797-809. 2015
    ....
  12. doi request reprint No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials
    Lisette M Wiltink
    Lisette M Wiltink, Remi A Nout, Marta Fiocco, Elma Meershoek Klein Kranenbarg, Cornelis J H van de Velde, Carien L Creutzberg, and Corrie A M Marijnen, Leiden University Medical Center, Leiden Ina M Jürgenliemk Schulz, University Medical Center Utrecht, Utrecht Jan J Jobsen, Medisch Spectum Twente, Enschede Iris D Nagtegaal, Radboud University Medical Center, Nijmegen and Harm J T Rutten, Catharina Hospital Eindhoven, Eindhoven, The Netherlands
    J Clin Oncol 33:1640-6. 2015
    ..This study investigated the long-term probability of developing a second cancer in a large pooled cohort of patients treated with surgery with or without radiotherapy (RT)...
  13. doi request reprint High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
    Ellen Stelloo
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Gynecol Oncol 133:197-204. 2014
    ..Therefore, the objective was to determine whether molecular analysis of pre-operative endometrial cancer samples accurately reflects those alterations in the subsequent hysterectomy specimens...
  14. doi request reprint Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands Electronic address
    Int J Radiat Oncol Biol Phys 91:530-9. 2015
    ..To facilitate treatment decision support for individual patients, accurate statistical models to predict locoregional relapse (LRR), distant relapse (DR), overall survival (OS), and disease-free survival (DFS) are required...
  15. doi request reprint Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy
    Joeke M Felderhof
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Acta Oncol 52:745-52. 2013
    ..To evaluate long-term local control, survival, radiation side effects and functional outcome after limb-sparing surgery followed by postoperative radiotherapy (RT) for soft tissue sarcoma (STS)...
  16. doi request reprint Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
    Ellen Stelloo
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 28:836-44. 2015
    ..High frequencies of targetable alterations were identified and may serve as targets for individualized treatment. ..
  17. doi request reprint A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial
    Lisette M Wiltink
    a Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands and
    Acta Oncol 55:502-8. 2016
    ....
  18. doi request reprint Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy
    Rinske M Bakker
    Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
    J Sex Med 12:764-73. 2015
    ..Regular vaginal dilator use is thought to reduce vaginal shortening and/or tightening, but compliance is poor...
  19. pmc The role of radiotherapy in endometrial cancer: current evidence and trends
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Curr Oncol Rep 13:472-8. 2011
    ..Current ongoing trials are exploring the role of combined RT and chemotherapy, compared to chemotherapy or RT alone...
  20. pmc POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
    Inge C van Gool
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Clin Cancer Res 21:3347-55. 2015
    ..In view of the emerging data linking mutation burden, immune response, and clinical outcome in cancer, we investigated whether POLE-mutant endometrial cancers showed evidence of increased immunogenicity...
  21. doi request reprint Outcome of advanced, unresectable conventional central chondrosarcoma
    Annemiek M van Maldegem
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Cancer 120:3159-64. 2014
    ..Therefore, the authors conducted this retrospective, 2-center study to gain insight into the outcome of patients with advanced, unresectable, conventional central chondrosarcoma...
  22. doi request reprint Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method
    Rinske Maria Bakker
    Departments of Gynecology, and Clinical Oncology, Leiden University Medical Center, Leiden and Departments of Radiotherapy, and Gynecology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
    Int J Gynecol Cancer 24:1499-506. 2014
    ..This study aimed to reach consensus among professional experts on patient information provision and support regarding sexual rehabilitation and vaginal dilator use after radiotherapy (RT) for gynecological cancers...
  23. pmc The clinical approach toward giant cell tumor of bone
    Lizz van der Heijden
    Departments of Orthopedic Surgery, Clinical Oncology, Radiology, and Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Oncologist 19:550-61. 2014
    ..Denosumab was recently registered for unresectable disease. Moderate-dose radiotherapy (40-55 Gy) is restricted to rare cases in which surgery would lead to unacceptable morbidity and RANKL inhibitors are contraindicated or unavailable. ..
  24. pmc Prognostic significance of POLE proofreading mutations in endometrial cancer
    David N Church
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK DNC, IPMT Oxford Cancer Centre, Churchill Hospital, Oxford, UK DNC Department of Pathology ES, NTH, VTHBMS, TB and Department of Clinical Oncology RAN, CLC, Leiden University Medical Center, Leiden, the Netherlands Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland NV, AN, PJW Vesalius Research Center VRC, VIB, Leuven, Belgium JD, DL Laboratory of Translational Genetics, Department of Oncology, KU Leuven, Belgium FA, DL Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Gasthuisberg, Leuven, Belgium FA Genomic Medicine Theme, Oxford Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK IPMT Department of Radiation Oncology, University Medical Centrum Utrecht, the Netherlands IMJS Department of Radiation Oncology
    J Natl Cancer Inst 107:402. 2015
    ..We examined whether POLE proofreading mutations, recently reported in about 7% of ECs, predict prognosis...
  25. doi request reprint Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial
    Lisette M Wiltink
    Department of Clinical Oncology, Leiden University Medical Center, P O Box 9600, 2300 RC Leiden, The Netherlands
    Eur J Cancer 50:2390-8. 2014
    ..The current study investigates the long-term health-related quality of life (HRQL) of patients 14 years after treatment in the Dutch TME trial...